CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
- Enrollment completed for Phase 2 COVID-19 study with mono- and bivalent vaccine candidates; study on track for data read-out in early 2024
- First participant dosed in seasonal flu Phase 2 study with potentially differentiated multivalent candidate; €15 million milestone payment by GSK triggered
- Phase 1 study in glioblastoma well on track with opening of third dose level for CVGBM, CureVac’s multiepitope cancer vaccine candidate
- Preclinical data with multiepitope construct in oncology shows strong T cells responses and significantly extended survival in checkpoint-inhibitor resistant melanoma model
- Infringement ruling on four intellectual property rights postponed by Regional Court Düsseldorf pending separate validity ruling in German patent litigation against BioNTech; postponement suggests court will find all four rights to be infringed
- The RNA Printer® achieved first milestone, obtaining manufacturing license for GMP-grade mRNA manufacturing in cancer vaccine development
- Chief Business and Commercial Officer to leave CureVac at the end of his term, effective November 30, 2023
- Cash and cash equivalents position of €464.1 million as of September 30, 2023
- CureVac to host conference call and webcast today at 9 a.m. ET / 3 p.m. CET
CureVac N.V. (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the third quarter and first nine months of 2023 and provided a business update.